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Abstract
Laromustine is an experimental sulfonylhydrazine prodrug used in late-stage clinical
studies against acute myeloid leukemia (AML) and glioblastoma multiforme (GBM). Despite
initial promise for both indications, clinical trials for GBM have not been as successful as those
for AML. To investigate methods for improving the effectiveness of laromustine in GBM and to
learn more about the mechanism of action of laromustine, a chemical genetic screen will be
conducted to identify agents that sensitize GBM cells to the anti-proliferative effects of
laromustine. The library, which will include approximately 450 FDA-approved drugs, will be
screened using a newly optimized high throughput assay based on the Click-iT EdU Microplate
Assay kit (Molecular Probes). Optimization of the assay has required determining the proper cell
seed density, drug concentration and incubation time, and fluorescent substrate concentration,
among other variables. It was determined that low cell seed densities allow for maximal
proliferation and a high signal-to-noise ratio. Furthermore, 50 µM laromustine was found to have
little inhibitory effect on the proliferation of U138 cells, while higher laromustine concentrations
yielded a sharp decrease in proliferation. These results suggest that reduced proliferation of cells
exposed to 50 µM laromustine in combination with library compounds is a suitable marker for
sensitization to laromustine. With these optimization data, a chemical screen can now be
conducted, potentially revealing new therapeutic strategies to treat GBM.
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Introduction
As the second leading cause of death in the United States, cancer continues to be a
pressing biomedical problem.1 It is estimated that a half of men and a third of women in the
United States will be diagnosed with cancer at some point in their lives, leaving few people
unaffected by the disease in some way.2 In actuality, cancer is not a single disease, but a family
of illnesses characterized by rapid, uncontrolled cell growth. It is often initialized by a small
number of causal mutations that promote growth or impede growth suppression, leading to a
wide range of further genetic and epigenetic changes as cell cycle checkpoints are bypassed. The
heterogeneity of mutations encumbers treatment development, as even a single tumor can
contain cells with wildly dissimilar genetic profiles. Consequently, many chemotherapeutic
treatments help only a small percentage of cancer patients, and the need for scientists to identify
new biological targets, to develop new treatments, and to further elucidate the bioactivities of
current therapies persists.
One agent that has shown promise in preclinical and clinical studies is laromustine, a
sulfonylhydrazine prodrug used in late-stage clinical studies against acute myeloid leukemia
(AML) and glioblastoma multiforme (GBM). Laromustine (also known as 101M, VNP40101M,
cloretazine, and Onrigin) is activated through base-catalyzed decomposition into two
electrophilic components, a chloroethylating agent that can modify the O-6 position of guanine
in DNA and a carbamoylating agent that is less understood (Figure 1).3 The alkylation of guanine
molecules in DNA is considered the main anticancer activity of laromustine, as it leads to G-C
ethane interstrand crosslinks that disrupt DNA replication.3,4 Laromustine is considered
somewhat selective toward cancer cells because they are often deficient in O6-alkylguanineDNA alkyltransferase (AGT), a protein that repairs O-6 guanine alkylations.3 Most cancer cells
3

maintain some AGT activity, but each AGT molecule can only repair a single guanine
chloroethylation.3,5 Thus, cells that have moderate to low levels of AGT are still sensitive to
laromustine. There is also a fairly short window when AGT is effective, as AGT is able to repair
the chloroethyl monoadduct but not the subsequent crosslink.6 Moreover, laromustine has been
shown to have a very favorable pharmacokinetic profile, with a longer half-life and similar
DNA-crosslinking ability compared to similar compounds.4

Figure 1. Base-catalyzed decomposition pathway of laromustine.4
Preclinical experiments in mouse models have suggested that laromustine has great
therapeutic potential. One study showed that laromustine was able to cure 100% of mice at the
lowest concentration (10-15 mg/kg/day for 6 days) and with the lowest toxicity (6% decrease in
body weight) compared to similar sulfonylhydrazine compounds.7 As a class of drugs,
sulfonylhydrazine compounds have been shown to be effective anticancer agents.8 Some of the
sulfonylhydrazine compounds to which laromustine was compared were in clinical trials at the
time the preclinical study was published, suggesting that laromustine could be even more
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effective than contemporary experimental treatments. Additional studies demonstrated that
laromustine could effectively cure mice of leukemia, colon carcinoma, human glioblastoma
xenographs, and murine lung carcionoma.9 The ability of laromustine to pass the blood brain
barrier in mice was exceptionally impressive, as it eradicated a greater number of cranial
leukemia cells than BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea), one of the leading
experimental central nervous system neoplasm treatments. It also had a more favorable toxicity
profile than BCNU. Due to these auspicious preclinical results, laromustine was advanced to
clinical trials.10
In the clinic, laromustine has had some success in treating AML, its primary indication.
Only one third of adults with AML, the most common type of acute leukemia in adults, can be
cured using current treatment.11 AML also affects children, though the average age of diagnosis
is 68 years old.12 The current standard treatment, involving doses of daunorubicin and
cytarabine, can induce complete remission in 60-80% of young and 40-60% of older newlydiagnosed patients, but many patients later suffer a relapse that is then resistant to the
treatment.11 Daunorubicin interacts with DNA–topoisomerase II and triggers apoptosis.13
Cytabarine is a cytosine analog, inhibiting DNA synthesis.10 Laromustine has been proposed as a
potential alternative to these treatments, producing a complete response with limited
extramedullary toxicity in 50% of elderly de novo AML patients in a phase II trial.12
Furthermore, the effectiveness of laromustine against AML was enhanced by administering it in
concert with cytarabine, and laromustine and cytarabine were effectively able to treat some
patients with refractory leukemia.10
Clinical results for the second indication of laromustine, GBM, have been somewhat less
propitious. GBM is the most common form of malignant primary brain tumor, and also one of
5

the most deadly.14 It represents approximately 60% of all gliomas.15 The current standard of
treatment, radiotherapy followed by doses of temozolomide, is by no means a cure; the mean
survival time is approximately 13.4 months after diagnosis.15 Temozolomide is a DNA
methylating agent that acts at several locations, the most cytotoxic of which is the O-6 position
of guanine.16 Researchers are continuing to investigate alternative treatments to prolong the lives
of patients. Unfortunately, laromustine has not been very effective in the clinical studies for
GBM conducted thus far. For example, laromustine was only able to produce six-month
progression-free survival in 6% of adults with recurrent glioblastoma in a phase II study.17 The
median progression-free survival time was 6.3 weeks. Similar studies were also done in children
with glioblastoma, with comparable results.18 However, the clinical studies conducted were very
limited and often only included patients that did not respond to initial temozolomide
treatments.17,19 Furthermore, studies to find effective partner drugs for laromustine in GBM
patients have not been conducted despite clinical evidence that laromustine and temozolomide
are compatible and were effective in curing some patients with refractory AML.20
The limited toxicity of laromustine, its compatibility with other drugs in clinical trials,
and its ability to pass the blood-brain barrier suggest that it has potential for GBM treatment if
researchers can optimize its use. Traditionally, the effects of laromustine on cancer cells have
been studied one biological pathway or component at a time in the laboratory. However, the two
active components of laromustine are both very reactive electrophiles, implying that they have
the potential for broad reactivity within cells and that the mechanism of laromustine is likely
very complex. As an illustration of the complexity of laromustine’s action, we demonstrated that
laromustine only halted reproduction in U138 human GBM cells rather than inducing acute
cytotoxicity as it does in HL-60 acute promyelocytic leukemia cells (data not shown). A better
6

understanding of laromustine could inform clinical use of the drug, identifying the patients that
will benefit most from its use and also suggesting compounds that could complement
laromustine’s activity.
An efficient way to study multiple facets of laromustine’s mechanism of action in a
single experiment is to screen its anti-proliferative function against a library of well-understood
small molecules. High-throughput screening has become increasingly popular in pharmacology,
both to identify new therapeutic options and to further understand current treatments, as it allows
researchers to study wide ranges of biochemical components and pathways simultaneously.
Chemical genetic screens follow from traditional genetics experiments. However, rather than
using a mutagenic agent to manipulate gene expression as in traditional genetics, chemical
genetics uses small molecules to perturb biochemical pathways through interactions with
proteins. In forward chemical genetics, the model system, often tissue cultures or primitive
multicellular organisms, is exposed to a diverse compound library. The compounds are then
evaluated on their ability to create a particular phenotype. Once the effective molecules have
been identified, the molecules can be studied individually and in depth to understand how they
produce the desired phenotype. Alternatively, an individual protein can be studied through
reverse chemical genetics, in which the compounds are first screened for the ability to interact
with a particular biomolecule. Hits are then administered in a model system to observe the
resultant phenotype and decipher the function of the protein of interest.
The libraries of small molecules used in these chemical genetic screens typically include
hundreds or even thousands of compounds. They are generally selected to maximize the diversity
of chemical structure, providing the potential to affect varied proteins and bioprocesses.
Chemical genetic screens have become even more viable as automated liquid handling systems
7

have minimized the manual labor and the imprecision inherent in working with such large
collections of compounds. Chemical genetics has revolutionized the drug discovery process and
has especially shown promise in the realm of orphan diseases, finally making it affordable to find
treatments, if not cures, for devastating diseases that affect a relatively small percentage of the
population for which there are no therapeutics currently available.21
Chemical genetic screens have been particularly effective when they have used libraries
composed of FDA-approved compounds. The mechanisms of those compounds have already
been extensively studied and are well-characterized, and thus any positive results in a screen
should correspond directly to specific bioprocesses. Moreover, these screens often have
extraordinary and unexpected results. In one study conducted in zebrafish, rosuvastatin,
traditionally used to treat high cholesterol, was identified as an antiangiogenic compound that
can suppress prostate cancer growth.22 As a second, equally surprising example, riluzole,
currently used to slow the progression of amyotrophic lateral sclerosis, was found to increase
wnt/ß-catenin signaling, effectively fighting melanoma.23
As a drug that has already shown compatibility with several other small molecules,
laromustine is a suitable candidate compound to study in a chemical genetic screen. The study
presented herein aims to further the current understanding of the mechanism of laromustine in
GBM and to identify potential partner drugs for laromustine. To this end, a high throughput
assay based on the Click-iT EdU Microplate Assay kit (Molecular Probes) was newly optimized
for use in a chemical genetic screen (Figure 2). The screen will identify compounds that enhance
the anti-proliferative capabilities of laromustine in U138 GBM cells. The assay development
process required optimization of many parameters, including the reagent concentrations,
incubation times, and cell seed density. The determined conditions produce reproducible
8

1. Preparation EdU-labeled
DNA from lysed cells is fixed
to the well bottoms.

2. Click Reaction Oregon Green 488
azide is attached to the incorporated
EdU via a copper(I)-catalyzed
cycloaddition reaction.

3. Signal Amplification Horseradish peroxidase-conjugated
antibodies (purple) bind Oregon Green 488. Horseradish
peroxidase catalyzes a reaction between Amplex UltraRed
(red triangles) and hydrogen peroxide to create the detected
fluorescent molecule (red suns).

Figure 2. Outline of the Click-iT EdU Microplate Assay used to measure cell
proliferation. Cells are seeded in a multiwell plate, treated as desired, and provided with
EdU (5-ethynyl-2’-deoxyuridine), which proliferating cells incorporate into new DNA.
The DNA is fixed to the plate bottom (1), Oregon Green 488 is bound to the DNA (2),
and the signal is amplified through a multiple step procedure (3).
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results with low error and a high signal-to-noise ratio. Now that optimization has been
completed, these data will soon be used to conduct the aforementioned chemical screen,
potentially revealing new therapeutic strategies to treat GBM.

Materials and Methods
Cell Culture
U138 human glioblastoma cells (American Type Culture Collection, Rockville, MD)
were grown in Eagle Minimum Essential Medium (Lonza, Walkersville, MD) supplemented
with 0.1% gentamycin (Thomas Scientific, Swedesboro, NJ), 1% L-glutamine (Lonza), and 10%
fetal bovine serum (Lonza). Cells were maintained at 45-90% confluence at 37°C and 5% CO2.
Prior to performing experiments, cells were washed twice with HEPES buffer (Lonza) and
incubated with trypsin/EDTA (Lonza) at room temperature for 3 min to detach them from the
flask surface. The trypsin was then neutralized with trypsin neutralizing solution (Lonza), and
cells were spun at 200 x g for 5 min. After centrifugation, the supernatant was removed, and cells
were resuspended in fresh media. Cell viability was assessed by trypan blue (Lonza) exclusion,
and cells were counted using a Cellometer Auto T4 (Nexcelom Bioscience, Lawrence, MA).
Click-iT EdU Proliferation Assay Optimization
Spectrophotometer Signal Range
Quinine sulfate was used to determine the appropriate signal range for the
spectrophotometer and to determine whether the instrument being used measures overall quantity
of fluorescent molecules or their concentration. Volumes of 20, 40, 60, 80, and 100 µL of 10 µM
quinine sulfate in 0.5 M H2SO4 were added to wells in triplicate. Fluorescence was read using a
10

top-reading SpectraMax M2 (Molecular Devices, Sunnyville, CA) with excitation of 320 nm and
emission of 460 nm. To determine whether there was an optimal well volume for the
spectrophotometer, 20 µL of 10 µM quinine sulfate in 0.5 M H2SO4 was added to wells and
adjusted to a volume of 20, 40, 60, 80, or 100 µL with 0.5 M H2SO4. Fluorescence measurements
were made as above. All volumes were tested in triplicate.
EdU Incubation
Prior to treatment, cells were seeded at 3,000 cells/well with 25 µL of media in a 384well white µClear plate (Greiner Bio-One, Monroe, NC). Cells were incubated at 37°C and 5%
CO2 for 24 hr, after which time the media was aspirated and replaced with drug-treated media.
The drug-treated media was prepared by diluting laromustine/DMSO solutions 1:1000 in media
for final laromustine concentrations of 12.5, 25, 50, 100, and 200 µM. An equivalent volume of
DMSO in media was used as the negative control. The plates were incubated for 24 hr at 37°C
and 5% CO2 prior to proliferation measurements.
The Click-iT EdU Microplate Assay (Molecular Probes, Eugene, OR) was used to
measure cell proliferation after treatment, adapted to a 384-well plate by using one quarter of the
manufacturer suggested well volumes for a 96-well plate. EdU (5-ethynyl-2’-deoxyuridine), a
thymidine analog, was added to wells for a final concentration of 5, 10, 15, and 20 µM. Wells
without EdU were used as negative controls. EdU incubation lasted 12 or 24 hr at 37°C and 5%
CO2, after which time the manufacturer’s instructions were followed to develop the plate and
quantify EdU incorporation. Briefly, media was removed, cells were lysed, and DNA was fixed
to plate bottoms. A copper(I)-catalyzed cycloaddition reaction was performed to attach an
Oregon Green 488 azide to the incorporated EdU based on the click reaction developed by Fokin
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and Sharpless.24 An anti-Oregon Green 488 antibody with horseradish peroxidase conjugate was
then used to amplify the signal, using Amplex UltraRed as the substrate to generate the detected
fluorescent signal. The plate was read using the SpectraMax M2 plate reader, with excitation of
544 nm and emission of 590 nm. All conditions were tested in duplicate.
Seed Density and Fluorescent Substrate Concentration
Once the optimal signal range was determined from the quinine experiments and the
proper EdU quantity was identified, the cell seed density and Amplex UltraRed concentration
were varied to determine the appropriate conditions for the Click-iT EdU Microplate Assay.
Cells were plated at 300, 1500, 3000, and 6000 cells/well in 25 µL of media and incubated for 48
hr at 37°C and 5% CO2. Wells with media and no cells were used as negative controls. Media
was aspirated from wells and replaced with 25 µL of a 1:1000 DMSO/media solution. The plate
was incubated under the same conditions for 12 hr. Then 5 µM EdU was added to each well, and
the plate was incubated for 12 hr. The plate was developed as previously described except that
the amount of Amplex UltraRed was varied to adjust the signal, using half, three quarters, or all
of the volume suggested by the manufacturer. All conditions were tested in quadruplicate.
An additional experiment was also performed to refine the appropriate seed density
range. Cells were plated at 250, 500, 750, 1000, and 1250 cells/well in 25 µL media and
incubated for 48 hr at 37°C and 5% CO2. Wells with media and no cells were used as negative
controls. Media was aspirated from wells and replaced with 25 µL of a 1:1000 DMSO/media
solution. The plate was incubated under the same conditions for 12 hr. Then 5 µM EdU was
added to each well, and the plate was incubated for 12 hr. The plate was developed as previously
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described, using the manufacturer suggested amount of Amplex UltraRed. All conditions were
tested in quadruplicate or quintuplicate.
Drug Concentration
To determine the appropriate amount of laromustine to expose cells during the chemical
screen, cells were plated at 500 cells/well in 25 µL of media. Wells with media and no cells were
again used as negative controls. The plate was incubated for 48 hours at 37°C and 5% CO2.
Media was aspirated from wells and replaced with 0, 12.5, 25, 50, 100, or 200 µM laromustine in
media, prepared as described previously, and allowed to incubate for 6 hr. EdU was then added
as previously described. The manufacturer instructions were followed to measure the
proliferation, again using a 12 hr EdU incubation period and using the manufacturer suggested
quantity of Amplex UltraRed. All laromustine concentrations were tested in quintuplicate, while
the DMSO control was performed in quadruplicate, and wells with media treated with each drug
concentration but without cells were evaluated in triplicate. The experiment was then repeated to
verify results, except that the DMSO control was performed in quintuplicate and conditions were
tested in quadruplicate or quintuplicate.

Results and Discussion
Spectrophotometer fluorescence depends on the total quantity of fluorophore in the sample and
not on its concentration
Prior to optimization, it was important to determine the range of fluorescence that is
reliably detectable by the SpectraMax M2 and how fluorescence is detected. Ideally, the assay
conditions used would maximize the difference between background signal and the signal from
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the most proliferative cells, the DMSO control cells that are not exposed to laromustine.
However, the signal from the DMSO control cannot be so high that it saturates the instrument’s
ability to measure fluorescence. Furthermore, it was not understood whether the fluorescent
readout from the spectrophotometer was indicative of the concentration of fluorophore or the
number of fluorescent molecules in the sample. Different volumes of 10 µM quinine sulfate in
0.5 M sulfuric acid were used to generate a standard curve to determine the instrument’s upper
limit for measuring fluorescence. Quinine sulfate is a recognized standard fluorophore that has
long been used to calibrate spectrophotometers and other fluorescence instruments due to its
consistent, strong fluorescence.25 Volumes of quinine sulfate ranging from 20 to 80 µL
maintained a linear relationship with the fluorescence readings (Figure 3). However, 100 µL of
quinine sulfate did not follow this trend, but rather showed that the signal was beginning to
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Figure 3. Fluorescence of quinine sulfate in relative fluorescent units as a function of
volume of 10 µM quinine sulfate in 0.5 M sulfuric acid in wells of a 384-well plate. Data
are reported in technical triplicate ± standard deviation. The trend line does not include
the final data point.
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saturate the instrument between 5x104 and 6x104 relative fluorescent units (RFU). Therefore, to
obtain reliable data with the largest difference between background and maximum signal, the
fluorescence readings from wells of U138 cells treated with 1:1000 DMSO in media, the
negative control, should be near or below 5x104 RFU.
Additionally, this experiment demonstrated that the number of fluorescent molecules, and
not the concentration of the fluorophore, was the important factor in determining the fluorescent
readout. All of the wells had the same concentration of quinine sulfate but provided different
fluorescence. To verify this conclusion, the fluorescence of samples with the same quantity of
fluorophore but concentrations ranging from 1 µM to 10 µM quinine sulfate in 0.5 M H2SO4 was
determined. The different concentrations were tested in triplicate. Although the concentrations
varied, there was no significant difference in fluorescent signal (data not shown). Another
important result from these experiments is that the instrument was able to reproducibly measure
the fluorescence of small volumes of quinine solutions, despite the narrowness of the wells in the
384-well plate. This was a concern for conducting the Click-iT EdU assay in a 384-well plate, as
the ending volume for the assay in a 384-well plate is only 27.5 µL of the 100 µL well capacity
and the kit was designed for use in 96-well plates, which have much wider wells. Based on these
results, however, the 27.5 µL should be ample volume for the spectrophotometer to reliably
detect the assay fluorescence.
Small EdU concentration and short incubation period provides best signal range
Several rounds of experimentation needed to be conducted to optimize the Click-iT EdU
Microplate Assay for the current screen. The manufacturer recommends first adjusting the
amount of EdU and the incubation time with EdU. Cells were exposed to 0 to 200 µM
laromustine for 24 hours. They were then provided amounts of EdU ranging from half to double
15
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Figure 4. Proliferation of cells seeded at 3000 cells/well exposed to varying amounts of
laromustine, measured 24 hr (A) or 12 hr (B) after addition of different EdU
concentrations. Data are reported as the mean of duplicate experiments expressed as a
percent of the proliferation of control cells treated with 1:1000 DMSO/media ± standard
error.
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the recommended 10 µM for 12 or 24 hrs. Many of the tested conditions showed no significant
difference in proliferation between cells treated with 200 µM laromustine and the negative
control cells, suggesting that the amount of EdU or the incubation time was too long to register a
difference between inhibited and uninhibited proliferation (Figure 4).
With both the 12 and 24 hr incubation, however, the 5 µM EdU condition showed an
adequate separation in measured proliferation between cells exposed to 0 and 200 µM
laromustine (Figure 5). Because the results from the 12 and 24 hr conditions were not
significantly different, a 12 hr incubation was chosen for all further experiments to make the
assay maximally efficient.
140
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Control

120
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12 hr EdU

60

24 hr EdU

40

20
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10
-20

100
Concentration of Laromustine (µM)

Figure 5. Proliferation of cells seeded at 3000 cells/well exposed to varying amounts of
laromustine, measured 12 hr or 24 hr after addition of 5 µM EdU. Data are reported as
the mean of duplicate experiments expressed as a percent of the proliferation of control
cells treated with 1:1000 DMSO/media ± standard error. Data selected from those shown
in Figure 4.
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Recommended Amplex UltraRed quantity with low seed density gives appropriate fluorescence
The next round of optimization focused on adjusting the conditions to achieve a
fluorescence signal of about 5x104 RFU from the control condition, in which cells were exposed
to 1:1000 DMSO in media rather than laromustine. Three main methods of adjusting the
fluorescence produced in the Click-iT EdU Microplate assay are to change the amount of EdU
provided to the cells, adjust the cell seed density, and modify the amount of the detected
substrate that is added. The amount of anti-Oregon Green antibody with horseradish peroxidase
conjugate could also be adjusted. However, it is important for the limiting factor in measuring
the fluorescence to be the proliferation and the number of incorporated EdU molecules.
Reducing the antibody concentration could lead to a situation in which there are incorporated
EdU molecules that are not detected, and it would be difficult to distinguish between high and
low levels of proliferation. Of the three other options, the EdU quantity was ruled out as it was
already reduced to a level lower than the manufacturer recommended quantity. Thus, the seed
density and the amount of detected Amplex UltraRed were manipulated. The seed density ranged
from 300 to 6000 cells/well. Visually, a density of 300 cells/well appears sparse under the
microscope, while 6000 cells/well approaches 100% confluence. All cells were provided with the
1:1000 DMSO in media control treatment. During development, the full amount, three-quarters,
or half of the recommended quantity of Amplex UltraRed was pipetted to each well. All
treatments were evaluated in quadruplicate.
Ultimately, it was determined that the recommended amount of Amplex UltraRed with
lower seed densities was preferable to achieve the correct fluorescent signal (Figure 6). All three
Amplex UltraRed data sets yielded curves with the same contour. They were also fairly evenly
spaced, with about 1.5x104 RFU between the 1x and 0.75x data points and between the 0.75x
18
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Figure 6. Proliferation of cells seeded in a 384-well plate at various densities measured
12 hr after addition of the EdU using different quantities of Amplex UltraRed, expressed
relative to the manufacturer recommended amount. Data are reported in relative
fluorescence units as the mean of quadruplicate experiments ± standard error.

and 0.5x data points. This was even true when the 1x Amplex UltraRed data points far exceeded
the previously determined optimal signal level of 5x104 RFU. These findings suggest that the
Amplex UltraRed is simply a signal amplifier, with a linear relationship between Amplex
UltraRed available and the fluorescence signal achieved.
The relationship between cell density and fluorescence was not linear. Instead, the curve
plateaued after 1500 cells/well. Because all three Amplex UltraRed data plots exhibit the same
curvature, the plateau is likely an indication of decreasing rates of proliferation rather than
fluorescent signal saturation. Highly dense cell populations often proliferate at a slower rate
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because resources such as nutrients and surface space on which to adhere become scarce. The
large amount of standard error in the highest seed density data demonstrates that proliferation
cannot be precisely determined at such a high density, possibly because some of the cells begin
to die. It is also important to note that the results from the first round of experimentation, in
which the appropriate EdU concentration was determined, were obtained using the second
highest seed density, which is within the proliferation plateau. This may explain why such little
difference was seen between the measured proliferation of the negative control cells and the cells
exposed to laromustine.
To more precisely determine the seed density at which the proliferation begins to plateau,
the experiment was repeated using the manufacturer recommended quantity of Amplex UltraRed
and 500 to 1500 cells/well (Figure 7). The 1x Amplex UltraRed condition was chosen because it
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Figure 7. Proliferation of cells seeded in a 384-well plate at various low densities
measured 12 hr after the addition of EdU using the manufacturer recommended quantity
of Amplex UltraRed. Data are reported in relative fluorescence units as the mean of
quadruplicate experiments (white points) or quintuplicate experiments (black points) ±
standard error.
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approached 5x104 RFU even at low seed densities, allowing for the fluorescent signal to be
maximized. Conditions were tested in quadruplicate or quintuplicate. The fluorescent signal
plateaued even at these low seed densities. In fact, the plateau began at a seed density of 500
cells/well, suggesting that that is the greatest seed density that can be used to have the maximal
fluorescence and maximal proliferation. Therefore, 500 cells/well will be used as the seed
density for all future assays.
50 µM laromustine does not significantly inhibit U138 proliferation
For the screen to have the highest throughput, only one concentration of laromustine
should be used. Low concentrations of laromustine will not significantly inhibit proliferation of
U138 cells. However, at a certain critical concentration, laromustine begins to affect cell
proliferation potently. The ideal laromustine concentration for the screen is a concentration that
is slightly lower than the critical inhibitory concentration. In such a situation, the cells exposed to
laromustine will show little to no inhibition, but the cells exposed to laromustine along with a
library compound that sensitizes cells to laromustine will proliferate at a markedly lesser rate. To
determine what this ideal concentration is in U138 cells, the Click-iT EdU assay was repeated
using the previously determined conditions and laromustine concentrations ranging from 0 to
200 µM (Figure 8A). The proliferation of cells exposed to up to 50 µM laromustine was
comparable to the proliferation of cells not exposed to laromustine. However, the proliferation of
cells exposed to 100 µM or more was strongly inhibited, with a fluorescent signal of less than
35% of the signal from the DMSO control cells. These data suggest that 50 µM laromustine
would be a suitable concentration for the chemical genetic screen.
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Figure 8. Proliferation of cells seeded at 500 cells/well exposed to varying amounts of
laromustine, measured 12 hr after addition of 5 µM EdU. Data are reported as the mean
of quadruplicate experiments (white points) or quintuplicate experiments (black points)
and expressed as a percent of the proliferation of control cells treated with 1:1000
DMSO/media ± standard error. The DMSO control was performed in quadruplicate (A)
or quintuplicate (B).
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This experiment was then repeated to ensure that the results were reproducible. The
results during this second experiment were slightly different, with all points except the 12.5 µM
point appearing lower than in the first experiment (Figure 8B). Here 50 µM of laromustine seems
to be enough to inhibit proliferation modestly. Nonetheless, there is still an appreciable drop in
fluorescent signal between 50 and 100 µM laromustine, resulting in the same change in
proliferation between the 50 and 100 µM cells in the second experiment as in the first
experiment. As such, even though the numbers are not quite consistent, both trials suggest that
50 µM is the appropriate laromustine concentration for the chemical screen.

Future Work
With the Click-iT EdU assay fully optimized, a chemical genetic screen can now be
performed to identify compounds that sensitize U138 GBM cells to laromustine. The screen will
be conducted through collaboration with Dr. Robert Wheeler at the University of Maine in
Orono using the National Clinical Collection compound library, which contains approximately
450 FDA-approved drugs. Positive hits during the screen will be defined as those that
significantly inhibit the proliferation of U138 cells in concert with laromustine relative to control
experiments. The positive hits will then be studied more extensively.
Compounds found to enhance the anti-proliferative effects of laromustine must be
validated for their therapeutic relevance as partner drugs for laromustine. The cytotoxicity of the
positive hit compounds in combination with laromustine will be evaluated in noncancerous cell
lines. To be considered for therapeutic application, it is important that the admixtures of drugs
demonstrate some preference for cytostatic activity in neoplastic cells relative to healthy cells. It
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would also be of interest to determine whether AML cells are sensitive to the identified drug
combinations, as laromustine has been used to treat AML as well.
Independent of the possibility of identifying new therapeutic strategies, the known
pharmacology of any molecules that emerge in the screen will provide valuable information
about the mechanism of action of laromustine. As approved drugs, the library compounds have
been extensively studied and their mechanisms are largely known. Thus, the positive hits in the
screen will suggest biochemical pathways that laromustine may be manipulating. Comprehensive
literature research and considerable biochemical analysis will then be necessary to precisely
determine how the small molecules are complementing each other within the cell.
Ultimately, this chemical genetic screen has the potential to reveal novel therapeutic
strategies for a devastating human cancer. The results could suggest new combination therapies
for GBM or identify heretofore unrecognized subpopulations of GBM patients in which
laromustine would be particularly effective. The information will move us closer to developing a
successful treatment program for GBM patients, curing them of this calamitous disease or at
least prolonging their lives.
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